Under a settlement agreement, Insmed agreed to stop selling Iplex in the U.S. as a treatment for growth deficiencies and to withdraw an application for approval in Europe. A jury had found Insmed infringed patents held by Genentech and licensed to Tercica. Insmed will be able to develop Iplex for certain other diseases, with possible involvement by Genentech and Tercica.

Full Story:

Related Summaries